Piper Jaffray Companies Lowers Integra Lifesciences (NASDAQ:IART) to Neutral

Piper Jaffray Companies cut shares of Integra Lifesciences (NASDAQ:IART) from an overweight rating to a neutral rating in a research report sent to investors on Tuesday, January 7th, Briefing.com Automated Import reports. Piper Jaffray Companies currently has $58.00 price objective on the life sciences company’s stock, down from their prior price objective of $59.00.

A number of other research firms have also recently commented on IART. Oppenheimer set a $68.00 target price on shares of Integra Lifesciences and gave the stock a buy rating in a research note on Friday, October 25th. Royal Bank of Canada set a $62.00 price target on shares of Integra Lifesciences and gave the stock a hold rating in a research report on Friday, October 25th. ValuEngine lowered shares of Integra Lifesciences from a sell rating to a strong sell rating in a research report on Thursday, November 14th. UBS Group boosted their price target on shares of Integra Lifesciences from $63.00 to $65.00 and gave the stock a neutral rating in a research report on Wednesday, December 18th. Finally, BidaskClub lowered shares of Integra Lifesciences from a hold rating to a sell rating in a research report on Tuesday, January 7th. Two research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the stock. Integra Lifesciences presently has a consensus rating of Hold and an average target price of $62.17.

IART stock traded up $0.57 during trading on Tuesday, hitting $58.89. 142,315 shares of the company’s stock traded hands, compared to its average volume of 365,275. The company has a quick ratio of 1.92, a current ratio of 2.92 and a debt-to-equity ratio of 1.07. The business has a fifty day simple moving average of $59.59 and a two-hundred day simple moving average of $59.41. Integra Lifesciences has a 1 year low of $45.07 and a 1 year high of $65.09. The firm has a market capitalization of $5.02 billion, a P/E ratio of 24.33, a PEG ratio of 1.58 and a beta of 1.10.

Integra Lifesciences (NASDAQ:IART) last issued its earnings results on Thursday, October 24th. The life sciences company reported $0.68 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.03. The firm had revenue of $379.10 million during the quarter, compared to analysts’ expectations of $376.85 million. Integra Lifesciences had a net margin of 3.99% and a return on equity of 16.83%. The firm’s revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.59 earnings per share. On average, equities research analysts predict that Integra Lifesciences will post 2.74 EPS for the current fiscal year.

In other news, major shareholder Richard E. Caruso sold 491,205 shares of the company’s stock in a transaction that occurred on Thursday, December 19th. The shares were sold at an average price of $59.42, for a total value of $29,187,401.10. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $7,970,242.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Eric Schwartz sold 4,007 shares of the company’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $62.25, for a total transaction of $249,435.75. Corporate insiders own 4.50% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in IART. Quadrant Capital Group LLC increased its stake in Integra Lifesciences by 239.0% during the 3rd quarter. Quadrant Capital Group LLC now owns 556 shares of the life sciences company’s stock worth $31,000 after buying an additional 392 shares during the period. Penserra Capital Management LLC purchased a new stake in Integra Lifesciences during the 3rd quarter worth approximately $126,000. World Asset Management Inc purchased a new stake in Integra Lifesciences during the 3rd quarter worth approximately $200,000. Coldstream Capital Management Inc. purchased a new stake in Integra Lifesciences during the 3rd quarter worth approximately $200,000. Finally, Sciencast Management LP purchased a new stake in Integra Lifesciences during the 4th quarter worth approximately $248,000. 79.91% of the stock is currently owned by hedge funds and other institutional investors.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Article: Percentage Decliners

Analyst Recommendations for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.